Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Alpha-1 adrenergic blocker indicated in benign prostatic hyperplasia (BPH) in adult males.
Oral administration once a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its high percentage of protein binding (EMA 2018) makes transfer into milk in significant amounts unlikely.
Its low oral bioavailability, reduced further with the consumption of fatty foods, such as milk (EMA 2018), hinders its transfer to the infant’s plasma from the breastmilk ingested, except in premature babies and the immediate neonatal period when there may be greater intestinal permeability.
Possible side effects are not serious or frequent (EMA 2018).